1196732-52-1

Basic information

• Product Name: Propargyl-PEG8-amine
• Synonyms: Propargyl-PEG8-amine;HC≡C-CH2-PEG8-NH2;Propyne-PEG8-amine;Alkyne-PEG8-NH2
• CAS NO: 1196732-52-1
• Molecular Formula: C₁₉H₃₇NO₈
• Molecular Weight: 407.49898
• Mol File: 1196732-52-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Solubility: Soluble in Water, DMSO, DCM, DMF
• CAS DataBase Reference: Propargyl-PEG8-amine(CAS DataBase Reference)
• NIST Chemistry Reference: Propargyl-PEG8-amine(1196732-52-1)
• EPA Substance Registry System: Propargyl-PEG8-amine(1196732-52-1)

Safety Data

• Hazardous Substances Data: 1196732-52-1(Hazardous Substances Data)

Usage

Description

Propargyl-PEG8-amine is a heterobifunctional reagent consisting of a propargyl group and an amine group. The amine group can form amide bonds with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. The propargyl group can form triazole linkage with azides in copper catalyzed Click Chemistry reactions.

Uses

Propargyl-peg8-amine is used as a reactant in the synthesis of synthetic antibody mimics targeting prostate cancer.

Upstream product

• 1351556-82-5 toluene-4-sulfonic acid 2-(2-{2-[2-(2-{2-[2-(2-prop-2-ynyloxyethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethyl ester 
• 1351556-81-4 2-(2-{2-[2-(2-{2-[2-(2-prop-2-ynyloxyethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethanol 
• 5117-19-1 octaethylene glycol 
• 1422540-96-2 C₂₇H₃₉NO₁₀ 
• 1422540-85-9 C₂₀H₃₈O₁₁S 
• 352439-36-2 α-(2-azidoethyl)-ω-hydroxyhexa(oxyethylene) 
• 1196733-06-8 1-azido-3,6,9,12,15,18,21,24-octaoxaheptacos-26-yne 

Downstream Products

• 1196732-55-4 N-(2,4-dinitrophenyl)-3,6,9,12,15,18,21,24-octaoxaheptacos-26-yn-1-amine 
• 1196732-45-2 (S)-2-(3-((S)-1-carboxy-5-(4-(25-(2,4-dinitrophenylamino)-2,5,8,11,14,17,20,23-octaoxapentacosyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioic acid 
• 1422541-07-8 C₄₆H₆₅N₃O₁₄S₂ 

Relevant articles and documents

Facial Synthesis and Bioevaluation of Well‐Defined OEGylated Betulinic Acid‐Cyclodextrin Conjugates for Inhibition of Influenza Infection

Betulinic acid (BA) and its derivatives exhibit a variety of biological activities, especially their anti‐HIV‐1 activity, but generally have only modest inhibitory potency against influenza virus. The entry of influenza virus into host cells can be competitively inhibited by multivalent derivatives targeting hemagglutinin. In this study, a series of hexa‐, hepta‐ and octavalent BA derivatives based on α-, β-and γ-cyclodextrin scaffolds, respectively, with varying lengths of flexible oligo(ethylene glycol) linkers was designed and synthesized using a microwave‐assisted copper‐catalyzed 1,3‐di-polar cycloaddition reaction. The generated BA‐cyclodextrin conjugates were tested for their in vitro activity against influenza A/WSN/33 (H1N1) virus and cytotoxicity. Among the tested com-pounds, 58, 80 and 82 showed slight cytotoxicity to Madin‐Darby canine kidney cells with viabilities ranging from 64 to 68% at a high concentration of 100 μM. Four conjugates 51 and 69–71 showed significant inhibitory effects on influenza infection with half maximal inhibitory concentration val-ues of 5.20, 9.82, 7.48 and 7.59 μM, respectively. The structure‐activity relationships of multivalent BA‐cyclodextrin conjugates were discussed, highlighting that multivalent BA derivatives may be potential antiviral agents against influenza infection.

Comparative binding and uptake of liposomes decorated with mannose oligosaccharides by cells expressing the mannose receptor or DC-SIGN

Mannose Receptor (MR) and DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) are two mannose-specific targets for antigens carried by liposomes but DC-SIGN is more specific of DCs. Here, DC targeting is addressed by using DPPC/D

TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR_ARMS)

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.